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Aim. Ovarian epithelial dysplasia was initially described in material from prophylactic oophorectomies performed in patients
at genetic risk of ovarian cancer. Similar histopathological abnormalities have been revealed after ovulation stimulation. Since
infertility is also a risk factor for ovarian neoplasia, the aim of this study was to study the relationship between infertility and
ovarian dysplasia. Methods. We blindly reviewed 127 histopathological slides of adnexectomies or ovarian cystectomies according
to three groups—an exposed group to ovulation induction (n = 30), an infertile group without stimulation (n = 35), and a
spontaneously fertile control group (n = 62)—in order to design an eleven histopathological criteria scoring system. Results. The
ovarian dysplasia score was signiﬁcantly higher in exposed group whereas dysplasia score was low in infertile and control groups
(resp., 8.21 in exposed group, 3.69 for infertile patients, and 3.62 for the controls). In the subgroup with refractory infertility there
was a trend towards a more severe dysplasia score (8.53 in ovulation induction group and 5.1 in infertile group). Conclusion. These
results raise questions as to the responsibility of drugs used to induce ovulation and/or infertility itself in the genesis of ovarian
epithelial dysplasia.
1.Introduction
Histopathological study of material from prophylactic oo-
phorectomies performed for a genetic predisposition of
ovarian cancer revealed cytological and architectural abnor-
malities considered to be precancerous manifestations, and
termed “dysplasia” by analogy with the pre-invasive lesions
described for the genital tract (vulva, vagina, cervix, endo-
metrium) [1]. Several studies have found similar ovarian
dysplasia lesions after stimulation of ovulation in infertile
patients, without any indication of their long-term evolution
[2, 3]. However, the relationship between ovulation induc-
tion and ovarian dysplasia is not obvious because infertility
in itself represents a confounding factor [3]. The question is
whether the lesions are somehow related to the infertility or
are due to the ovulation stimulation.
Theaimofthisstudyistodeterminetherelationshipbet-
ween infertility and ovarian epithelial dysplasia.
2. Methods
2.1. Patients. Using a database covering 1.400 adnexectomies
and/or ovarian cystectomies carried out between January
1995 and December 2000, we selected three groups.
G r o u pA :A nE x p o s e dG r o u p . Who had adnexectomies and/
or ovarian cystectomies after in vitro fertilization using ovu-
lation induction several years later and whose ovaries were2 Obstetrics and Gynecology International
Figure 1: Nuclear abnormalities in ovarian epithelial dysplasia
(HES, ×40), from Dr. L. Deligdisch collection.
reported as normal on routine histological examination. We
felt it would be interesting to study more particularly those
cases in which there will be failure of stimulation. We called
this subgroup “refractory infertility.”
Group B: An Infertile Group. Without ovulation induction
who had adnexectomies and/or ovarian cystectomies prior
to any assisted reproductive treatment (ART) technique and
whose ovaries were reported as normal on routine histolog-
ical examination. They did not receive ovulation induction
before the surgery. We felt it would be interesting to study
more particularly those cases of infertility in which there
will be failure of stimulation. We called this sub-group
“refractory infertility.”
Group C: Control Group. We selected a spontaneously fer-
tile population, with no personal nor family history of gy-
naecologic neoplasia (breast, ovary, endometrium), who un-
derwent adnexectomy and/or cystectomy for which the his-
topathological examination concluded that the ovaries
showed no sign of cancerous or borderline pathology.
2.2. Histopathological Criteria. Our deﬁnition of ovarian
atypia was based on previous studies of ovarian dysplasia,
that is, dysplasia described in ovaries from patients with
a genetic risk (prophylactic oophorectomy for BRCA1/2
mutation) [4–6], in areas that appeared to be “healthy” adja-
cent to an ovarian cancer [7, 8], in the apparently healthy
contralateral ovary in case of unilateral ovarian cancer
[9, 10], and in stimulated ovaries [2, 3]. This scoring
system (eleven histopathological criteria) was designed in
our previous study about the relationship between ovarian
dysplasia and ovulation induction [3]:
epithelial pseudostratiﬁcation,
epithelial proliferation,
surface papillomatosis,
irregular nuclear chromatin pattern (Figure 1),
irregular nuclear contour,
cellular pleiomorphism,
increase in nuclear size
inclusion cysts,
deep epithelial invaginations,
psammoma,
stromal hyperplasia.
In each case, the least normal area was given a score
between 0 and 2 (0: normal, 1: moderately abnormal, 2:
severely abnormal), whether located on the surface or in an
inclusion cyst.
An overall dysplasia score was then obtained for each
patient by simply adding the scores for each of the 11 items
(total range: 0 to 22).
Morphological studies were processed on 3 micron
paraﬃnsectionsstainedwithstandardhaematoxylinphloxin
safran(HPS).Thenumberofsectionsavailableforreviewfor
e a c hc a s er a n g e df r o m8t o1 1i nb o t hs t u d yg r o u p s .
The histopathology slides were all reexamined blinded
by two pathologists who were expert in oncogynaecology.
When several slides were available, the one with the highest
dysplasia score was retained. Concerning the cystectomies,
the slides were re-examined on the one hand to conﬁrm
the histopathological diagnosis and on the other to look for
associated ovarian tissue in order to establish the dysplasia
score. If there was no ovarian tissue the ﬁle was excluded.
In the event of obvious diﬀerences between the scores
established by each pathologist, a further examination was
carried out to reach a consensus.
2.3. Statistical Analysis. Our main measurement was the
mean dysplasia score. Student’s t-test was used to compare
the dysplasia score means of both groups.
3. Results
All the included patients are eligible.
30 exposed patients (group A), 35 infertile patients
(group B), and 62 fertile controls (group B) were included
in the study. There were 18 “refractory infertility”patients in
group A and 21 “refractory infertility” patients in group B.
Thecharacteristicsandtheindicationsofsurgeryofthethree
groups are given in Table 1.
Histopathological features of excised material from
group A, B, and C were mainly benign cysts (resp., 30 cysts,
32 cysts, and 40 cysts) without cancer or borderline tumor.
Histopathological analysis is given in Table 2.
Infertility was female in 70% of cases in group A and
71% of cases in group B, with the following distribution: in
group A, ovarian dysovulation 10%, tubal pathology 40%,
endometriosis 50% and in group B, ovarian dysovulation
4%, tubal pathology 36%, and endometriosis 60%.
The cytological and architectural abnormalities of the
ovarian epithelium described by our score were always
assessed in the ovarian tissue. The histopathological abnor-
malities in both groups are described in Table 3. Histopatho-
logical anomalies were always present in group A whereas
t h e yw e r er a r ei ng r o u pB .
Based on this data, a mean dysplasia score was deter-
minedforbothgroups:8.21forgroupA,3.69fortheinfertileObstetrics and Gynecology International 3
Table 1: Characteristics of the study population at the time of
surgery.
Variables
Exposed
group A
N = 30
Infertile
group B
N = 35
Control
group C
N = 62
Age (years) 38,5
(29–50)
30.5
(21–43)
42.1
(32–51)
BMI 23,1 23.4 22.6
Surgical indication
Metrorrhagia 6 0 20
Pelvic pain 18 8 39
Cyst at ultrasound 30 30 35
Hydrosalpinx 0 3 0
Ovarian biopsies 0 3 0
Nulliparity 5 29 0
Parity 1,1 (1–3) 0 (0-1) 2.7 (1–4)
Use of oral contraception 25, or 83% 28, or 80% 55, or 89%
Duration of exposure to
oral contraception
(months)
40,1 (4–91) 26.5
(0–134)
58.2
(20–180)
Table 2: Histopathological diagnosis on excised tissues.
Exposed
group
(group A)
Infertile
patients
(group B)
Controls
(group C)
Pyosalpinx 0 0 5
Hydrosalpinx 0 3∗ 0
Endometrioma 9 15 12
Serous ovarian cystadenomas 6 3 5
Mucinous ovarian
cystadenomas 256
O v a r i a n m y o m a 025
Follicular ovarian cyst 10 3 9
Haemorrhagic ovarian cyst 3 3 17
Torsion/ischaemia of the
adnexa 003
Ovarian biopsies (ovarian
reserve) 04 ∗ 0
∗The 3 patients presenting a hydrosalpinx had several ovarian biopsies.
patients,and3.62forthecontrols.Thediﬀerencewasstatisti-
cally diﬀerent between group A and C (P<0.0001). How-
ever, there was no signiﬁcant diﬀerence between group B and
C( P = 0.92), nor were any statistically signiﬁcant diﬀerences
found according to the aetiology of infertility.
In the “refractory sterility” group, the dysplasia score was
higher in group A than in group B: 8.53 for group A and 5.1
for group B, P = 0.02.
An estimate of the study’s power is 0.99.
4. Discussion
Ovarian dysplasia was initially described in ovaries with a
genetic risk of cancer [1, 4, 5]. By analogy with preinvasive
cervical lesions, the generic term “dysplasia” was proposed.
The fact that these ovaries could evolve towards malignancy
if prophylactic ovariectomy did not take place led to the idea
that ovarian epithelial dysplasia was the missing link prior to
neoplasia.
Morerecentlysimilarovarianlesionsdescribedasdyspla-
siaweredetectedinovariesstimulatedduringIVFtreatment.
Nieto et al. [2] were the ﬁrst to ﬁnd signiﬁcant abnormalities
in stimulated ovaries compared to a control population.
One of our previous studies conﬁrmed these results (mean
dysplasia score 7.64) and also showed that a time eﬀect and a
dose eﬀect were probable [3]: histopathologic abnormalities
(cf photo) would become more severe and greater in number
with an increasing number of stimulation cycles (>3) and
after a suﬃcient lapse of time (over seven years). However it
isimpossibletopredicthowtheywouldevolve:thedysplastic
proﬁle of stimulated ovaries and ovaries with genetic risk
is not the same, which would tend to indicate a diﬀerent
evolution at long term [11, 12]. Animal experiments gave
some interesting conclusions. Ovulation in rats has resulted
in increased Ki67 expression and dysplastic abnormalities
in the ovarian epithelium [13]. C ¸elik et al. [14] found also
a relationship between the number of ovulation-inducted
cycles and the severity of ovarian dysplasia: when comparing
the rate of ovarian dysplasia in three groups of rats subjected
to one, three, and six gonadotrophin cycles, there was
a signiﬁcant trend towards more severe dysplasia as the
number of inducted ovulation cycles increased. Ozcan et al.
[15] have examined the eﬀects of ovulation induction agents
onovarianepitheliumafter6and12cycles:ovariandysplasia
(more severe after 12 cycles) was found to be signiﬁcant
in the ovaries of rats that were given clomiphene citrate,
recombinant FSH, and human menopausal gonadotrophin.
However no malignant ovarian lesion was found in these
three animal studies.
Patients undergoing ovarian stimulation could be at in-
creased risk of ovarian tumors (8.21 versus 3.62): few studies
have discussed the possible relationship between exogenous
hormones and the risk of developing borderline malignancy
of the ovary [11, 12, 16]. Therefore, the discovery of ovarian
dysplasia in stimulated ovaries raises the question of the
possibleresponsibilityofthetreatmentusedtoinduceovula-
tion. So two questions require an answer.
Firstly, is ovarian dysplasia a histopathologic entity, or a
simple variant from normal?
Secondly, is infertility or ovulation induction a risk fac-
tor for dysplasia, and could it be held responsible for the
appearance of dysplastic abnormalities?
(1) One of the major disadvantages of a histopathologic
score is that there will be subjectivity when applying it.
There is no consensual dysplasia scoring scheme. So we
designedanexhaustivescoringsystemfordysplasiainovaries
at genetic risk and in ovaries in relation with ovulation
induction [3, 17, 18]. Although we do not separate cellular
changes in inclusion cysts and surface epithelium (ovarian
surface epithelial changes are rarer than in inclusion cysts)
[19], our histopathological dysplasia score seems to be
reproducible (review by several pathologists blinded to clini-
cal data and comparison with control group in order to4 Obstetrics and Gynecology International
Table 3: Comparison of respective frequencies of the 11 histopathologic abnormalities in our dysplasia scoring system.
Group A
N = 30
Group B
N = 35
Group C
N = 62
Statistical
diﬀerence P
Epithelial pseudostratiﬁcation 21 (70%) 11 (31.4%) 17 (27.4%)
P1 < 0.0001
P2 = 0.98
P3 = 0.002
Epithelial proliferation 16 (53.3%) 8 (22.8%) 23 (37%)
P1 = 0.007
P2 = 0.06
P3 < 0.0001
Surface papillomatosis 15 (50%) 7 (20%) 15 (24.1%)
P1 = 0.009
P2 = 0.8
P3 < 0.0001
Irregular nuclear chromatine
pattern 13 (43.3%) 7 (20%) 18 (29%)
P1 = 0.0042
P2 = 0.69
P3 = 0.001
Irregular nuclear contour 12 (40%) 11 (31.4%) 12 (19.3%)
P1 = 0.0012
P2 = 0.059
P3 = 0.08
Cellular pleiomorphism 19 (63.3%) 9 (25.7%) 21 (33.8%)
P1 = 0.0078
P2 = 0.32
P3 = 0.0045
Increased size of nucleus 14 (46.6%) 6 (17.1%) 13 (20.9%)
P1 = 0.0074
P2 = 0.86
P3 = 0.004
Inclusion cysts 21 (70%) 15 (42.8%) 31 (50%)
P1 = 0.032
P2 = 0.22
P3 = 0.004
Psammomas 5 (16.6%) 5 (14.2%) 4 (6.4%)
P1 = 0.017
P2 = 0.012
P3 = 0.8
Deep epithelial invaginations 15 (50%) 6 (17.1%) 11 (17.7%)
P1 < 0.0001
P2 = 0.99
P3 = 0.002
Stromal hyperplasia 11 (36.6%) 14 (40%) 10 (16.1%)
P1 < 0.0001
P2 = 0.0013
P3 = 0.78
P1:statisticaldiﬀerencesbetweengroupAandC.P2:statisticaldiﬀerencesbetweengroupBandC.P3:statisticaldiﬀerencesbetweengroupAandB.Statistical
analysis by Student’s t-test.
validate our dysplasia system in one of our previous studies)
[20] and consistent with the literature [4–10]. We have pro-
posed a cut-oﬀ in one of our latest studies: an ovarian
dysplasia score over than 8 (Se: 60%; Sp: 93.3%) [20].
Digitised morphometric analyses based on the degree of
stratiﬁcation and loss of polarity (by measuring the shortest
distance between the nucleus and basal membrane, cellular
density), and nuclear pleiomorphism (by measurement of
the circumference and surface area of the nucleus) [21],
or methods of nuclear karyometry (quantitative analysis of
nuclear texture) [22, 23] conﬁrm that dysplasia is indeed
a distinct histopathologic entity in its own right. Recent
immunohistochemistry and molecular studies gave similar
results,validating theconceptof“ovarian dysplasia”[24,25].
(2)Humanepidemiologicalstudiesfollowingupinfertile
patients have most often demonstrated an increased risk of
ovariantumour(cancerousorborderline),buttheresultsare
contradictory: some blame the infertility itself [26, 27] while
others lay the blame more on ovulation inducing agents [28,
29].
Our previous studies revealed signiﬁcant dysplastic
lesions in stimulated ovaries [3]. In the present study, there
were signiﬁcant dysplastic lesions in exposed group whereas
there was no increase in the dysplasia score in the infertile
patients, which is corroborated by the studies of nulliparous
patients by Nieto et al. [2].
Should we therefore conclude that treatments to induce
ovulation are responsible for the genesis of dysplasia?Obstetrics and Gynecology International 5
Our results show a signiﬁcant trend towards dysplasia
in case of refractory infertility in group A and B. However
other cofactors might be involved. Nieto et al. [30] also
explored the prevalence of ovarian cancer in patients who
were 1st degree relatives of women treated for infertility (due
to anovulation) compared with patients who were 1st degree
relatives of spontaneously fertile women: the result was a
relative risk of 1.45 (95% IC 0.36–10.55) and above all an
additional risk in patients who were 1st degree relatives of
patients presenting refractory infertility due to dysovulation
(14.8, IC 95% 1.36–160). The authors concluded in a
probable “genetic link” [30, 31]. A deletion or mutation in
an u m b e ro fg e n e sw h i c hr e g u l a t ec e l lc y c l ea n dc e l ld e a t h
in the ovary could aﬀect both fertility (through regulation
of follicle pool) and carcinogenesis (by increasing growth
stimilus and/or removing growth inhibition): for example,
in vitro studies have proved that mice deﬁcient in LATS1
are infertile and develop ovarian tumours [32]. Deletions of
Smad1 and Smad5 lead to infertility and ovarian cancer in
mice [33].
So our results could corroborate this genetic theory
by showing that this sub-group of patients with refractory
infertilitywouldbeatrisk,withtheovulationinducingdrugs
possibly acting as dysplasia revealers or accelerators.
Caution is needed when interpreting all this data: this is
a retrospective observational study with limited numbers of
patients.Infertility isacomplexandmultifactorialpathology
in which many confounding factors interfere (age, parity,
breastfeeding, dosage level, duration of contraception, etc.)
tothepointitisdiﬃculttocometoanyconclusionaboutrisk
factor. Although the study’s power is very good (0.99), we
cannot draw the conclusion that the ovulation stimulation
therapy might always cause ovarian dysplasia. However,
we can tell that there is sometimes some histopathological
abnormalities in ovaries in relationship with ART and
infertility. This is a legitimate and very important question
that needs more studies not only to describe the dysplastic
lesions more precisely but also to look for them in larger
series and for their relationships with ovulation inducing
drugs.
5. Conclusion
This study shows a signiﬁcant level of abnormalities after
ovarian stimulation whereas there is no increase in ovarian
epithelial dysplasia in infertile patients compared with fertile
patients; we can also note a trend towards a higher incidence
of dysplastic changes in “refractory infertility.”
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